UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 2.336

Sortiert nach

Efficacy and Safety of Lapatinib As First-Line Therapy for ErbB2-Amplified Locally Advanced or Metastatic Breast Cancer

Journal of clinical oncology, 2008-06, Vol.26 (18), p.2999-3005

2008

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and Safety of Gemtuzumab Ozogamicin in Patients With CD33-Positive Acute Myeloid Leukemia in First Relapse

Journal of clinical oncology, 2001-07, Vol.19 (13), p.3244-3254

2001

Link zum Volltext

Verfügbarkeit prüfen

Antibody–radiation conjugates for acute myeloid leukemia: an interview with Mark Berger

Future oncology (London, England), 2021-06, Vol.17 (18), p.2275-2277

Berger, Mark S

2021

Link zum Volltext

Verfügbarkeit prüfen

Daratumumab-225Actinium conjugate demonstrates greatly enhanced antitumor activity against experimental multiple myeloma tumors

Oncoimmunology, 2019-08, Vol.8 (8)

2019

Link zum Volltext

Verfügbarkeit prüfen

Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells

Blood, 2001-05, Vol.97 (10), p.3197-3204

2001

Link zum Volltext

Verfügbarkeit prüfen

Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin

Blood, 2001-08, Vol.98 (4), p.988-994

2001

Link zum Volltext

Verfügbarkeit prüfen

Like Raising a Child

Journal of clinical oncology, 2012-04, Vol.30 (10), p.1140-1141

BERGER, Mark S

2012

Link zum Volltext

Verfügbarkeit prüfen

Randomized phase II study of carboplatin and etoposide with or without obatoclax mesylate in extensive-stage small cell lung cancer

Lung cancer (Amsterdam, Netherlands), 2014-09, Vol.85 (3), p.420-428

2014

Link zum Volltext

Verfügbarkeit prüfen

Targeted lymphodepletion with a CD45-directed antibody radioconjugate as a novel conditioning regimen prior to adoptive cell therapy

Oncotarget, 2020-09, Vol.11 (39), p.3571-3581

2020

Link zum Volltext

Verfügbarkeit prüfen

Phase I Dose Finding Studies of Obatoclax (GX15-070), a Small Molecule Pan-BCL-2 Family Antagonist, in Patients with Advanced Solid Tumors or Lymphoma

Clinical cancer research, 2010-08, Vol.16 (15), p.4038-4045

2010

Link zum Volltext

Verfügbarkeit prüfen

Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia

Blood, 2005-08, Vol.106 (4), p.1183-1188

2005

Link zum Volltext

Verfügbarkeit prüfen

Obatoclax Mesylate, a Pan–Bcl-2 Inhibitor, in Combination with Docetaxel in a Phase 1/2 Trial in Relapsed Non–Small-Cell Lung Cancer

Journal of thoracic oncology, 2014-01, Vol.9 (1), p.121-125

2014

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics of Gemtuzumab Ozogamicin, an Antibody-Targeted Chemotherapy Agent for the Treatment of Patients with Acute Myeloid Leukemia in First Relapse

Journal of clinical pharmacology, 2001-11, Vol.41 (11), p.1206-1214

2001

Link zum Volltext

Verfügbarkeit prüfen

ACCLAIM-1 dose escalation: Determination of quaratusugene ozeplasmid and osimertinib recommended phase 2 dose (RP2D)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e15081-e15081

2023

Link zum Volltext

Verfügbarkeit prüfen

A phase 2 study of the cytotoxic immunoconjugate CMB-401 (hCTM01-calicheamicin) in patients with platinum-sensitive recurrent epithelial ovarian carcinoma

Cancer Immunology, Immunotherapy, 2003-04, Vol.52 (4), p.243-248

2003

Link zum Volltext

Verfügbarkeit prüfen

Lintuzumab-225Ac in Combination with Venetoclax in Relapsed/Refractory AML: Early Results of a Phase I/II Study

Blood, 2020-11, Vol.136 (Supplement 1), p.24-25

2020

Link zum Volltext

Verfügbarkeit prüfen

Iomab with Adoptive Cellular Therapy (Iomab-ACT): A Pilot Study of 131-I Apamistamab Followed By CD19-Targeted CAR T-Cell Therapy for Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma

Blood, 2021-11, Vol.138 (Supplement 1), p.4810-4810

2021

Link zum Volltext

Verfügbarkeit prüfen

Rapid reduction of peripheral blasts in older patients with refractory acute myeloid leukemia (AML) using reinduction with single agent anti-CD45 targeted iodine ( 131 I) apamistamab [Iomab-B] radioimmunotherapy in the phase III SIERRA trial

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.7048-7048

2019

Link zum Volltext

Verfügbarkeit prüfen

Modeling Targeted Lymphodepletion with Radiolabeled CD45 Antibody As a Promising Preparative Regimen Prior to Adoptive Cell Therapy or CAR-T

Blood, 2018-11, Vol.132 (Supplement 1), p.5682-5682

2018

Link zum Volltext

Verfügbarkeit prüfen

Feasibility of Administering Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] for Re-Induction and Targeted Conditioning in Older Patients with Active, Relapsed or Refractory AML without Lead-Lined Rooms: Sierra Trial Experience at MSKCC

Blood, 2019-11, Vol.134 (Supplement_1), p.5839-5839

2019

Link zum Volltext

Verfügbarkeit prüfen

Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading

Cancer research (Chicago, Ill.), 1988-03, Vol.48 (5), p.1238-1243

1988

Link zum Volltext

Verfügbarkeit prüfen

Abstract 760: Conjugation of daratumumab with 225actinium greatly increases its antitumor activity against multiple myeloma tumors

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.760-760

2018

Link zum Volltext

Verfügbarkeit prüfen

Actinium Labeled Daratumumab Demonstrates Enhanced Killing of Multiple Myeloma Cells over Naked Daratumumab

Blood, 2017-12, Vol.130, p.4427-4427

2017

Link zum Volltext

Verfügbarkeit prüfen

Preclinical Development of an Actinium-225-Labeled Antibody Radio-Conjugate Directed Against CD45 for Targeted Conditioning and Radioimmunotherapy

Blood, 2019-11, Vol.134 (Supplement_1), p.5601-5601

2019

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 2.336

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(2.070)
Mit Volltextzugriff
(2.056)

Publikationsform

5 weitere anzeigen...

Weniger anzeigen...

Sprache

2 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Efficacy and Safety of Lapatinib As First-Line Therapy for ErbB2-Amplified Locally Advanced or Metastatic Breast Cancer

Efficacy and Safety of Gemtuzumab Ozogamicin in Patients With CD33-Positive Acute Myeloid Leukemia in First Relapse

Antibody–radiation conjugates for acute myeloid leukemia: an interview with Mark Berger

Daratumumab-225Actinium conjugate demonstrates greatly enhanced antitumor activity against experimental multiple myeloma tumors

Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells

Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin

Like Raising a Child

Randomized phase II study of carboplatin and etoposide with or without obatoclax mesylate in extensive-stage small cell lung cancer

Targeted lymphodepletion with a CD45-directed antibody radioconjugate as a novel conditioning regimen prior to adoptive cell therapy

Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33‐positive acute myeloid leukemia in first recurrence

Phase I Dose Finding Studies of Obatoclax (GX15-070), a Small Molecule Pan-BCL-2 Family Antagonist, in Patients with Advanced Solid Tumors or Lymphoma

Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia

Obatoclax Mesylate, a Pan–Bcl-2 Inhibitor, in Combination with Docetaxel in a Phase 1/2 Trial in Relapsed Non–Small-Cell Lung Cancer

Pharmacokinetics of Gemtuzumab Ozogamicin, an Antibody-Targeted Chemotherapy Agent for the Treatment of Patients with Acute Myeloid Leukemia in First Relapse

ACCLAIM-1 dose escalation: Determination of quaratusugene ozeplasmid and osimertinib recommended phase 2 dose (RP2D)

A phase 2 study of the cytotoxic immunoconjugate CMB-401 (hCTM01-calicheamicin) in patients with platinum-sensitive recurrent epithelial ovarian carcinoma

Lintuzumab-225Ac in Combination with Venetoclax in Relapsed/Refractory AML: Early Results of a Phase I/II Study

Iomab with Adoptive Cellular Therapy (Iomab-ACT): A Pilot Study of 131-I Apamistamab Followed By CD19-Targeted CAR T-Cell Therapy for Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma

Rapid reduction of peripheral blasts in older patients with refractory acute myeloid leukemia (AML) using reinduction with single agent anti-CD45 targeted iodine ( 131 I) apamistamab [Iomab-B] radioimmunotherapy in the phase III SIERRA trial

Modeling Targeted Lymphodepletion with Radiolabeled CD45 Antibody As a Promising Preparative Regimen Prior to Adoptive Cell Therapy or CAR-T

Feasibility of Administering Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] for Re-Induction and Targeted Conditioning in Older Patients with Active, Relapsed or Refractory AML without Lead-Lined Rooms: Sierra Trial Experience at MSKCC

Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading

Abstract 760: Conjugation of daratumumab with 225actinium greatly increases its antitumor activity against multiple myeloma tumors

Actinium Labeled Daratumumab Demonstrates Enhanced Killing of Multiple Myeloma Cells over Naked Daratumumab

Preclinical Development of an Actinium-225-Labeled Antibody Radio-Conjugate Directed Against CD45 for Targeted Conditioning and Radioimmunotherapy

Suchergebnisse filtern